Investing in Tomorrow's Health

NCL Technology Ventures invests transformational equity capital in entrepreneurs who have truly innovative technologies.

Our Investment Strategy

We invest in Seed and Series A rounds where we can deploy our expertise and capital to help our companies achieve an early inflection point in valuation. We consciously choose investments that create an impact on the lives of patients as well as financial return for our investors.

Our Value Add:

We provide a package of human and capital resources over the life of our investments including:

  • – Strong scientific knowledge and frontline healthcare experience
  • – Developmental and leadership building experience
  • – A carefully built local and global network of healthcare specialists
  • – An overriding ambition to succeed in bringing new innovation in healthcare to benefit global recipients

 We are pleased with the performance of Fund 1 and have therefore decided to back Fund 2 as a cornerstone investor.”

– Health Technology Fund II LP

Our Portfolio

Our investments keep making strides in their fields and winning awards in recognition.

All Digital Health Medical Technologies Therapeutics
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo

NCLs Health Technology Fund II

NCL has recently launched it Health Technology Fund II.  The fund has been designed to take positions in pioneering new technologies that can create significant patient impact and produce upper quartile investment returns.

The fund has launched in partnership with several leading UK institutions including Kings College, NHS and our delivery partner Catalent Inc (NYSE: CLT). Documentation can be provided to professional investors only upon request.

Whether a potential investor or an entrepreneur we invite you to discuss your goals and ambitions with us.

Our Team

Our team spans three generations and is vastly experienced in venture investment, fund structuring, entrepreneurship and business management and is supported by an expert Scientific Advisory Board.

All Board of Directors International Investment Team Scientific Advisory Board Support Team
Jerry Biggs's headshot

Jerry Biggs

CEO
View Profile
Emma Sugrue's headshot

Emma Sugrue

Executive Assistant
View Profile
Jonathan Synett's headshot

Jonathan Synett

CIO
View Profile
Pat O’Neill's headshot

Pat O’Neill

President - US Operations
View Profile
Graham Hutchins's headshot

Graham Hutchins

Operations Director
View Profile
Chris Phillips's headshot

Chris Phillips

Executive Advisor
View Profile
Professor Clive Page's headshot

Professor Clive Page

View Profile
Professor Michelle Garrett's headshot

Professor Michelle Garrett

View Profile
Martin Riley's headshot

Martin Riley

View Profile
Julien Meissonnier's headshot

Julien Meissonnier

View Profile
Graeme Cox's headshot

Graeme Cox

View Profile

Our News

TC Biopharm stock up 31% as FDA grants orphan drug tag to leukemia treatment

U.S. Food and Drug Administration (FDA) has granted TC Biopharm (NASDAQ:TCBP) lead product, OmnImmune, orphan drug designation, to treat acute myeloid leukemia (AML). Shares of (TCBP) … Continued

Read more

Centauri Therapeutics closes £24 million GBP Series A investment round

London, UK, 16 February 2022: Centauri Therapeutics Limited (Centauri), an immunotherapy company founded by Animatrix Founders LLP and focused on the treatment of infectious diseases, … Continued

Read more

Curesponse Secures Additional USD 8 Million Funding for Its Breakthrough Precision Oncology Platform

REẖOVOT, Israel, November 15, 2021 (Newswire.com) – Curesponse (www.curesponse.com) has secured additional USD 8 million funding for its breakthrough precision oncology platform. Curesponse is a cancer precision … Continued

Read more

Getting Investment Ready

NCL Technology Ventures are delivering a 12-hour programme for aspiring Chief Executive’s and Chief Technology Officers on how to attract venture capital investment for their businesses.

The programme will be delivered on behalf of the South-East Innovation Programme (SE-IP) and provide early-stage entrepreneurs and companies with an overview of the fund-raising process from the point of view of a Venture Capitalist, including a checklist of requirements for an entrepreneur to complete when fund-raising and an opportunity to review their business plan/pitch-deck.

The programme is run over 2 days and takes 12 hours. It is open to entrepreneurs and businesses based in the South East Local Enterprise Partnership area (Essex, South-End, Grays, Kent and East Sussex).

If you are interested in participating contact us at seip@ncltv.co.uk .

The programme is being run on behalf of Maidstone Borough Council.

Learn more

 

Want to discuss an investment opportunity with us?

Submit an Opportunity